Dialysis-Related Amyloidosis Treatment Act of 2025
This bill adds specific Medicare coverage for treatments of dialysis-related amyloidosis, a condition affecting some long-term dialysis patients. It defines these treatments as FDA-approved items/services provided in dialysis facilities, including necessary adjunct supplies. Medicare will pay 100% of reasonable charges for these treatments separately, outside standard dialysis payment bundles. This directly affects Medicare beneficiaries receiving these specific treatments at approved dialysis facilities.
Bill status
in committee
1 of 4 stages cleared
Introduction
Jun 2025
Committee Review
Floor Vote
President
Introduced Jun 20, 2025
Last action Jun 20, 2025
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
2
Key actions
0
Committee
1
Jun 20, 2025
Committee
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
lower
Jun 20, 2025
Introduced
Introduced in House
lower
1 primary · 2 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Brian Babin
RRepublican
Co
David G. Valadao
RRepublican
Co
Jerrold Nadler
DDemocratic
Ask Maddy
·
AI policy assistant
Ask Maddy about HR 4055
Scope: US
Hi! I can help you understand HR 4055. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline